<DOC>
	<DOCNO>NCT01118780</DOCNO>
	<brief_summary>The purpose study test safety efficacy duloxetine versus placebo elderly patient suffer generalized anxiety disorder ( GAD ) .</brief_summary>
	<brief_title>A Study Duloxetine Elderly Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Have GAD base diagnostic criterion suffer adjustment disorder anxiety disorder otherwise specify . Symptoms GAD situational nature . Have Mini Mental State Examination ( MMSE ) score least 24 screen . Have Clinical Global Impressions Severity ( CGISeverity ) score great equal 4 screen randomization . Have Covi Anxiety Scale ( CAS ) score great equal 9 , item Raskin Depression Scale ( RDS ) may &gt; 3 , CAS score must great RDS screening . Have Hospital Anxiety Depression Scale ( HADS ) anxiety subscale score great equal 10 screening . Have degree understanding participant communicate intelligibly investigator study coordinator . Are judge reliable keep appointment able swallow require medication without open crush . Have current primary Diagnostic Statistical Manual Mental Disorders , Fourth EditionText Revised ( DSMIV TR ) Axis I diagnosis GAD , exception comorbid social phobia specific phobia . major depressive disorder ( MDD ) within past 6 month , panic disorder , posttraumatic stress disorder ( PTSD ) , eat disorder within past year , obsessive compulsive disorder ( OCD ) , bipolar affective disorder , psychosis , factitious disorder , somatoform disorder lifetime . The presence Axis II disorder , history antisocial behavior , participant , opinion investigator , poor medical psychiatric risk study compliance . Have organic mental disorder mental retardation diagnosis . Use benzodiazepine within 14 day prior randomization . Are judge clinically serious risk harm self others . Are currently enrol , discontinue within last 30 day , clinical trial involve offlabel use investigational drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have previously complete withdrawn study study investigate duloxetine previously treat duloxetine within past year participant lack response intolerability duloxetine ( approved indication ) clinically appropriate dose minimum 4 week . Have history alcohol psychoactive substance abuse dependence within past 6 month . Excessively use caffeine , opinion investigator . Have positive urine drug screen ( UDS ) substances abuse screening . Have serious medical illness . Have acute liver injury severe cirrhosis . Have abnormal thyroidstimulating hormone ( TSH ) concentration . Have initiate psychotherapy change intensity psychotherapy nondrug therapy ( acupuncture hypnosis ) within 6 week prior enrollment time study . Have take excluded medication within 7 day prior randomization . Have treat monoamine oxidase inhibitor ( MAOI ) fluoxetine within 30 day randomization potentially need use MAOI study within 5 day discontinuation study drug . Exhibit lack response current episode GAD 2 adequate trial antidepressant , benzodiazepine , anxiolytic clinically appropriate dose minimum 4 week . Have history severe allergy , hypersensitivity duloxetine inactive ingredient ; multiple adverse drug reaction ; transcranial magnetic stimulation ( TMS ) ; history seizure ; history psychosurgery electroconvulsive therapy ( ECT ) within 12 month . Have discontinue hormone replacement therapy within previous 3 month . Have uncontrolled narrowangle glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>GAD</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>Anxiety</keyword>
</DOC>